Prominent mental healthcare conditions including anxiety, depression, and PTSD have historically required complicated, resource intensive, and expensive treatments with broad range of range of effectiveness.
Many in the mental healthcare industry .
MINDCURE Announces Partnership with Speak Ai to Enhance iSTRYM, the Company s Psychedelic Digital Therapeutics Technology Platform
News provided by
Share this article
Share this article
Utilizing Speak Ai s technology, iSTRYM will provide Ai-driven intelligence to help therapists identify the most efficient and efficacious outcomes for patients of psychedelic assisted psychotherapy
VANCOUVER, BC, April 13, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( MINDCURE or the Company ) a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce that it has entered into a partnership with Speak Ai Inc. ( Speak Ai ). The Canadian-based technology company helps individuals and organizations analyze media, language, and metadata to automatically generate valuable insights through machine learning. MINDCURE will be integrating the platform s capabilities into iSTRYM, and will also work with Speak Ai to develop prop
While the tumultuous year that was 2020 brought numerous unforeseen challenges with it, psychedelic medicine made remarkable progress. With the new year in full swing, psychedelic companies are continuing to make their debut on the stock exchanges, making their mark on capital markets. After a fortuitous conference series in 2020, Psychedelic Capital, the premiere psychedelic due diligence conference, returns to highlight dignitaries from the top companies in the space.
The First Psychedelic Capital of 2021 Features Innovative Sponsors and Speakers
The first Psychedelic Capital event of 2021 is on January 28th at 4:30pm EST and will feature engaging presentations from our sponsors, Psygen Labs, Albert Labs and Mindset Pharma.